Skip to main content
SpringerLink
Log in

The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

We have given the selective 5 HT2 antagonist ritanserin in a dose of 10 mg twice daily for 4 weeks in a double-blind, randomized, placebocontrolled, parallel group study of 18 patients with untreated essential hypertension.

The fall in single platelet count due to 5 HT-induced platelet aggregation was significantly reduced by ritanserin compared with placebo (p<0.05).

There were no significant changes in supine or erect blood pressure or heart rate after ritanserin compared to placebo. Forearm blood flow, measured by mercury-in-strain gauge venous occlusion plethysmography, was not significantly altered by ritanserin.

Ritanserin caused prolongation of the QTc interval by 41 (SEM 11) ms (p<0.05 compared to placebo) but had no detectable effect on QRS duration, features suggestive of Class III antiarrhythmic activity.

These findings do not support an independent role of the 5 HT2 receptor in maintaining raised arterial pressure in essential hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, Vanhees L (1985) Ketanserin: A new hypotensive drug? J Cardiovasc Pharmacol 7 [Suppl 7]: S176-S182

    Google Scholar 

  • Antonaccio MJ, Taylor DG (1977) Reduction in blood pressure, sympathetic nerve discharge and centrally evoked pressor responses by methysergide in anaesthetised cats. Eur J Pharmacol 42: 331–338

    Google Scholar 

  • Bazett HC (1920) An analysis of the time relations of electrocardiograms. Heart 7: 353–370

    Google Scholar 

  • Conolan S, Quinn MJ, Taylor DA (1986) In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists. Br J Pharmacol 89: 129–135

    Google Scholar 

  • De Clerck F, Van Neuten JM, Reneman RS (1984) Platelet vessel wall interactions: Implication of 5-hydroxytryptamine. A review. Agents Actions 15: 612–626

    Google Scholar 

  • de Courcelles D de C, Leysen JE, De Clerck F, Van Belle H, Janssen PAJ (1986) Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J Biol Chem 260: 7603–7608

    Google Scholar 

  • De Cree J, Hoing M, De Ryck M, Symoens J (1985) The acute antihypertensive effect of ketanserin increases with age. J Cardiovasc Pharmacol 7 [Suppl 7]: S126-S127

    Google Scholar 

  • d'Inverno E (1980) Clinical use of plethysmography in the diagnosis of deep venous thrombosis and arterial occlusive disease, part 1. Angiology 31: 437–447

    Google Scholar 

  • Fagard R, Fiocchi R, Lijnen P, Staessen J, Moerman E, De Shaepdriver A, Amery A (1984) Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 51: 149–156

    Google Scholar 

  • Fenuik W, Humphrey PPA, Perren MJ, Watts AD (1985) A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: Evidence for different receptor sites obtained by use of selective agonists and antagonists. Br J Pharmacol 86: 697–704

    Google Scholar 

  • Gardner MJ, Altman DJ (1986) Statistics in medicine: Confidence intervals rather thanp values: Estimation rather than hypothesis testing. Br Med J 292: 746–750

    Google Scholar 

  • Gradin K, Petterson A, Hedner T, Persson B (1985) Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J Neural Trans 64: 145–149

    Google Scholar 

  • Hosie J, Stott DJ, Robertson JIS, Ball SG (1987) Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol 10 [Suppl 3]: S86-S88

    Google Scholar 

  • Janssen PAJ (1985) Pharmacology of potent and selective S2-serotonergic antagonists. J Cardiovasc Pharmacol 7 [Suppl 7]: S2-S11

    Google Scholar 

  • Kuhn DM, Wolf WA, Lovenberg W (1980) Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension 2: 243–255

    Google Scholar 

  • Leary WP, Reyes AJ, van der Byl K, Maharaj B (1987) Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorthiazide combination administered once daily. J Cardiovasc Pharmacol 10 [Suppl 3]: S127-S134

    Google Scholar 

  • Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of r 41468, a novel antagonist at 5HT-2 receptors. Life Sci 28: 1015–1022

    Google Scholar 

  • Leysen JE, Gommeron W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin, a very potent and long acting S2 antagonist. Mol Pharmacol 27: 600–611

    Google Scholar 

  • Lin MT, Chern SI (1979) Effect of brain 5-hydroxytryptamine alterations on reflex bradycardia in rats. Am J Physiol 236: R302-R306

    Google Scholar 

  • McCall RB, Schuette MR (1984) Evidence for an alpha1-receptor-mediated central sympathoinhibitory action of ketanserin. J Pharm Exp Ther 228: 704–710

    Google Scholar 

  • McKibben JK, Pocock WA, Barlow JB, Scott Millar RN, Obel IWP (1984) Sotalol, hypokalaemia, syncope and torsades de pointes. Br Heart J 51: 157–162

    Google Scholar 

  • Millar JS, Vaughan-Williams EM (1983) Pharmacological mapping of regional effects in the rabbit heart of some new anti-arrhythmic drugs. Br J Pharmacol 79: 701–709

    Google Scholar 

  • Saman S, Thandroyen F, Opie LH (1985) Serotonin and the heart: Effects of ketanserin on myocardial function, heart rate, and arrhythmias. J Cardiovasc Pharmacol 7 [Suppl 7]: S70-S75

    Google Scholar 

  • Saniabadi AR, Lowe GDO, Belch JJF, Forbes CD, Prentice CRM, Barbenel JC (1983) The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood. Thromb Haemostas 50: 718–721

    Google Scholar 

  • Saniabadi AR, Lowe GDO, Barbenel JC, Forbes CD (1984) A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: Additional evidence for a role of ADP. Thromb Haemostas 51: 115–118

    Google Scholar 

  • Staniforth DH (1984) Correction equation for ECG time intervals. Br J Clin Pharmacol 18: 115

    Google Scholar 

  • Stott DJ, Robertson JIS, Ball SG (1985) Specificity of the serotonergic antagonist ketanserin. J Hypertension 3 [Suppl 3]: S191-S193

    Google Scholar 

  • Stott DJ, McLenachan JM, Ball SG (1986) Ketanserin, the QT interval and autonomic function testing in normal subjects. Br J Pharmacol 21: 84P

  • Strano A, Novo S, Pinto A, Fasulo S, Alamo G (1985) Calf blood flow and vascular resistance in middle-aged and elderly hypertensives. J Hypertens 3 [Suppl 3]: S351-S353

    Google Scholar 

  • Surawicz B, Knoebel SB (1984) Long QT: Good, bad or indifferent. J Am Coll Cardiol 4: 398–413

    Google Scholar 

  • Tadepalli AS (1980) Inhibition of reflex bradycardia by a central action of 5-Hydroxytrypyophan. Br J Pharmacol 69: 647–650

    Google Scholar 

  • Van Neuten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982) Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit: effect of ketanserin (R 41 468). Eur J Pharmacol 77: 281–287

    Google Scholar 

  • Victorzon M, Tapparelli C, Muller-Schweinitzer E (1986) Comparison of the actions of serotoninergic agents on human saphenous veins and platelets. Eur J Pharmacol 124: 107–111

    Google Scholar 

  • Zabludowski JR, Ball SG, Robertson JIS (1985) Ketanserin and alpha-1-adrenergic antagonism in man. J Cardiovasc Pharmacol 7 [Suppl 7]: S125-S126

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Blood Pressure Unit, Western Infirmary, Glasgow, UK

    D. J. Stott

  2. University Department of Medicine, Royal Infirmary, Glasgow, UK

    A. R. Saniabadi & G. D. O. Lowe

  3. 1980 Great Western Road, Glasgow, UK

    J. Hosie

  4. Department of Cardiovascular Studies, The University, Leeds, UK

    S. G. Ball

  5. Department of Geriatrics, Gartnavel General Hospital, G12 0YN, Glasgow, UK

    D. J. Stott

Authors
  1. D. J. Stott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. R. Saniabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Hosie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. D. O. Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. G. Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stott, D.J., Saniabadi, A.R., Hosie, J. et al. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. Eur J Clin Pharmacol 35, 123–129 (1988). https://doi.org/10.1007/BF00609240

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00609240

Key words

Search

Navigation